ARCHIVES

Holden Center At U. Of Iowa Designated Comprehensive.

This article is from The Cancer Letter archive.

Vol. 27 No. 04 | January 26, 2001

Download PDF Visit The Full Archive

Related Articles

FDA Approves Iressa For Third-Line Treatment Of Non-Small Cell Lung Cancer

May 9, 2003

In Brief: Hammer Hears A Claim for The $1 Million Wynder’s Theory On Japan’s Colon Cancer Rates: Hamburgers

March 19, 1982

DCT board Okays Recompetition of Clinical Trials Contracts

October 29, 1993

Higher Response For Gleevec In Trial; CML Patients Allowed To Switch

January 25, 2002

Orphan Designation Granted To Advaxis HPV Immunotherapy

May 30, 2014

FDA Approves Ixempra For Metastatic Breast Cancer Resistant To Other Therapy

October 26, 2007